Literature DB >> 8176269

Absence of p53 gene mutations in cutaneous melanoma.

J Lübbe1, M Reichel, G Burg, P Kleihues.   

Abstract

Mutations in the p53 tumor suppressor gene are a common finding in many human malignancies. These mutations have been shown to inactivate the p53 protein and sometimes confer an oncogenic potential to the mutated gene. Type and pattern of p53 mutations may give clues to the tumor etiology, for example, ultraviolet-induced CC-->TT and C-->T transitions. Genomic DNA of 16 primary cutaneous melanomas of the superficial and nodular subtype and six melanoma metastases were screened for the presence of mutations in exons 5 to 8 of the p53 tumor suppressor gene, using the polymerase chain reaction and single-strand conformation polymorphism analysis, followed by direct DNA sequencing. We detected no mutations in any of the primary and metastatic melanomas in exons 5 to 8 of the p53 tumor suppressor gene. This indicates that, in contrast to skin carcinomas, p53 mutations are not operative in the evolution of human melanoma.

Entities:  

Mesh:

Year:  1994        PMID: 8176269     DOI: 10.1111/1523-1747.ep12381544

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  21 in total

1.  Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15.

Authors:  José Luis Soto Martínez; Carmen M Cabrera Morales; Sabio Serrano Ortega; Miguel Angel López-Nevot
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

2.  Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.

Authors:  Chi Luo; Jinghao Sheng; Miaofen G Hu; Frank G Haluska; Rutao Cui; Zhengping Xu; Philip N Tsichlis; Guo-Fu Hu; Philip W Hinds
Journal:  Cancer Res       Date:  2013-05-06       Impact factor: 12.701

3.  Dual inactivation of RB and p53 pathways in RAS-induced melanomas.

Authors:  N Bardeesy; B C Bastian; A Hezel; D Pinkel; R A DePinho; L Chin
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

4.  Leptomeningeal melanomatosis with multiple cutaneous pigmented nevi: tumor cell proliferation and malignant transformation in an autopsy case.

Authors:  H Oka; T Kameya; T Hata; N Kawano; K Fujii; K Yada
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

5.  Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma.

Authors:  A van Elsas; S F Zerp; S van der Flier; K M Krüse; C Aarnoudse; N K Hayward; D J Ruiter; P I Schrier
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

Review 6.  Melanoma genetics and the development of rational therapeutics.

Authors:  Yakov Chudnovsky; Paul A Khavari; Amy E Adams
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

7.  p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Authors:  Tamara Terzian; Enrique C Torchia; Daisy Dai; Steven E Robinson; Kazutoshi Murao; Regan A Stiegmann; Victoria Gonzalez; Glen M Boyle; Marianne B Powell; Pamela M Pollock; Guillermina Lozano; William A Robinson; Dennis R Roop; Neil F Box
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

Review 8.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

9.  Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.

Authors:  T Papp; M Jafari; D Schiffmann
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

10.  Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas.

Authors:  Yun Wang; John J Digiovanna; Jere B Stern; Thomas J Hornyak; Mark Raffeld; Sikandar G Khan; Kyu-Seon Oh; M Christine Hollander; Philip A Dennis; Kenneth H Kraemer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.